

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 October 2023 (26.10.2023)



(10) International Publication Number
WO 2023/202637 A1

(51) International Patent Classification:

C12N 9/88 (2006.01) A61K 38/46 (2006.01)
C12N 9/24 (2006.01) A61K 48/00 (2006.01)
C12N 15/86 (2006.01) A61P 25/14 (2006.01)
C12N 15/60 (2006.01) A61P 25/16 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2023/089291

(22) International Filing Date:

19 April 2023 (19.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/087771

19 April 2022 (19.04.2022)

CN

(71) Applicant: **SHANGHAI VITALGEN BIOPHARMA CO., LTD.** [CN/CN]; 3rd Floor, 665 Zhangjiang Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 201210 (CN).

(72) Inventors: **TAO, Yezheng**; Lv 4, 11 JiaLiLue Road, Block 2, Pudong New Area, Shanghai 201203 (CN). **TIAN, Shin-Shay**; Lv 5, 11 JiaLiLue Road, Block 2, Pudong New Area, Shanghai 201203 (CN). **ZHAO, Xiaoping**; Lv 5, 11 JiaLiLue Road, Block 2, Pudong New Area, Shanghai 201203 (CN).

(74) Agent: **IPFAITH PARTNERS**; Room 1003, 1005, 10th Floor, Telecom Industry Bldg. 65 Fuxing Rd., Haidian District, Beijing 100036 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2023/202637 A1

(54) Title: RECOMBINANT AAV VECTORS FOR TREATING NEURODEGENERATIVE DISORDERS

(57) Abstract: Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c) : (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADDC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.